Expert Opinion on Pharmacotherapy

Article	Citations
Pharmacotherapy developments in autophagy inhibitors for bladder cancer	42
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis	40
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy	39
Current treatment options for Mycobacterium marinum cutaneous infections	35
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives	35
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan	35
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten	33
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis	30
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases	29
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy	26
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook	25
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease	25
The pharmacological treatment and management of hyperhidrosis	24
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond	23
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children	22
Oral anticoagulation therapy in the setting of liver disease	21
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges	21
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma	20
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants	20
Pharmacotherapeutic options in pediatric obesity: an urgent call for further research	20
An up-to-date overview of the pharmacotherapeutic options for premature ejaculation	19
A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)	19
Pharmacotherapy of persistent genital arousal disorder/genito-pelvic dysesthesia: an updated review and data from a registry	18
When is pharmacotherapy necessary for the treatment of seasonal affective disorder?	18
Momelotinib in myelofibrosis	17

Correction	17
Selecting optimal therapy in systemic mastocytosis: current state and future directions	17
How useful is chemotherapy for atypical and anaplastic meningiomas?	16
Potential treatments for attention-deficit/hyperactivity disorder: a focus on Phase III trials	16
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy	16
Zanubrutinib for the treatment of chronic lymphocytic leukemia	16
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy	16
Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?	16
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis	16
Pharmacologic management of ET: established therapies and emerging agents	15
Pharmacotherapy of treatment-resistant hypertension in patients with chronic kidney disease	15
Expanding indications and developmental landscape of HER2-targeted therapies in breast cancer: a pharmacotherapeutic perspective	15
Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study	15
Rise and fall of decongestants in treating nasal congestion related diseases	15
Benefits and disadvantages of combination therapy with imeglimin and metformin in patients with type 2 diabetes	15
An update on current pharmacotherapy for vulvar cancer	14
The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder	14
Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review	14
An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies	14
Current advancements in pharmacotherapy for cancer cachexia	14
Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis	14
Correction	14
Evaluating pimavanserin tartrate as a treatment in Parkinson’s disease	13
Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes	13
Tirzepatide for overweight and obesity management	13
Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment	13
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature	13
What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?	13
Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs	13
Treating pediatric aggressive behaviors and comorbid conditions	13
Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy	13
Current pharmacological solutions for Behçet’s syndrome	13
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update	13
Upadacitinib in Crohn’s disease	13
An evaluation of the pharmacotherapeutic options for the treatment of adult phimosis. A systematic review of the evidence	12
Pharmacogenomics and pediatric drug development: science and political power. A narrative review	12
Approved medications for opioid use disorder : current update	12
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors	12
Pharmacotherapeutic strategies for the treatment of anorexia nervosa – novel targets to break a vicious cycle	11
Current and emerging COX inhibitors for treating postoperative pain following oral surgery	11
Drug treatment strategies for eosinophilic esophagitis in adults	11
Use of glucagon-like polypeptide 2 analogs for intestinal failure	11
Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy	11
Recent progress in the use of pharmacotherapy for endometrial cancer	11
An evaluation of pharmacological options for Cushing’s disease: what are the state-of-the-art options?	11
Pharmacotherapy for cervical cancer: current standard of care and new perspectives	11
Simnotrelvir as a potential treatment for COVID-19	11
Evidence-based prescribing of medications for ADHD: where are we in 2023?	11
Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper	11
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia	10

Pharmacological management of pituitary adenomas – what is new on the horizon?	10
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry	10
Pharmacological management of digital ulcers in systemic sclerosis - what is new?	10
Optimizing drug therapy for older adults: shifting away from problematic polypharmacy	10
Response to the letter to the editor: ‘Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia’	10
Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments	10
Evaluation of prescribing patterns of switching to and add-on lemborexant in patients treated with hypnotic medication: a nationwide claims database study in Japan	10
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?	10
An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma	10
Modern pharmacotherapy guidance for treating alcohol use disorders	10
Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals	10
Advances with androgen deprivation therapy for prostate cancer	10
Pharmacotherapy for Gastrointestinal Angiodysplasia: is it effective?	10
Current status of intracavernosal injection therapy in erectile dysfunction	10
Recent advances in Alzheimer’s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein	10
An overview of emergency pharmacotherapy for priapism	10
Melanoma and pediatric drug development: clinical progress vs. regulatory activism in minors - a narrative review	9
Reassessing the role of aspirin in patients with coronary artery disease	9
Pharmaceutical advances in the treatment of gastric adenocarcinoma	9
Current and emerging pharmacotherapies in Lennox-Gastaut syndrome	9
Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials	9
Recent advances in the pharmacotherapeutic management of diabetic kidney disease	9
Migraine in multiple sclerosis patients: potential links and treatment approach	9
Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024	9
Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done?	9
New antibiofilm strategies for the management of nontuberculous mycobacteria diseases	9
Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis	9
Advances in the pharmacotherapeutic management of refractory peptic ulcers	9
Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients	9
Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms	9
The management of cardiovascular disease risk in patients with rheumatoid arthritis	9
Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants	8
Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence	8
A review of pharmacokinetic data describing long-acting injectable cabotegravir during pregnancy	8
Time to reconsider the way of selecting antihypertensives for hypertensive left ventricular hypertrophy	8
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date	8
Will elinzanetant, a neurokinin receptor antagonist, have a role in the treatment of hot flashes?	8
Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder	8
An update on the pharmacotherapy of gout	8
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?	8
An update on antifungal resistance in dermatophytosis	8
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19	8
Risk management of medication errors: a novel conceptual framework	8
Clinical, metabolic, and immune interaction between tuberculosis and diabetes mellitus: implications and opportunities for therapies	8
Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature	8
An update on the pharmacological management of acne vulgaris: the state of the art	8
Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder	8
Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults	8
Combining finerenone with SGLT-2 inhibitors: building up CONFIDENCE for the treatment of diabetic kidney disease	8
Evaluating upadacitinib for the treatment of psoriatic arthritis	8
Effective risk reduction strategies and pharmacological treatment for uncomplicated recurrent urinary tract infections	8
Pharmacological management of migraine: current strategies and future directions	8
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy	8
Amyloidosis of the heart: pathophysiology, diagnosis, and treatment	8
Addressing the long-term risks of administering antenatal steroids	8
Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy	8
Recently approved and emerging drug options for migraine prophylaxis	8
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis	8
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization	8
Upadacitinib in Crohn’s disease: needs more insight	8
Pharmacological treatment for children with constipation: present and future	8
Clinical guidance for choosing the right pharmacotherapy for migraine attacks	8
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review	8
A comprehensive update on the pharmacological management of heterotopic ossification following hip arthroplasty: a level I evidenced based expert opinion	8
Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease	8
Advances in non-hormonal pharmacotherapy for the treatment of male infertility: the role of inositols	7
An evaluation of sebetralstat as the first oral on-demand therapy for Hereditary Angioedema	7
Identifying the challenges for successful pharmacotherapeutic management of sarcopenia	7
Glasdegib for the treatment of acute myeloid leukemia	7
Current pharmacological strategies for symptomatic reduction of persistent breathlessness – a literature review	7
A systematic review on effect of sodium-glucose cotransporter-2 inhibitors on the metabolic and endocrinological profile of patients with polycystic ovarian syndrome	7
Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature	7
Venetoclax and new BCL-2 inhibitors in acute myeloid leukemia	7
Pharmacological management of heart failure: a patient-centred approach	7
Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma	7
Metabolic-associated steatotic liver disease and hepatocellular carcinoma	7
New and emerging drugs for the treatment of invasive fungal infections	7
Promising therapies for the treatment of acromegaly	7
Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults	7
Pharmacotherapy in leishmaniasis: old, new treatments, their impacts and expert opinion	7

Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis	7
Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome	7
FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions	7
A large-scale database study for the prescription status of a new voltage-gated Ca2+ channel α2δ ligand, mirogabalin, in Japan	7
Pharmacotherapy for bipolar disorder in adults with high-functioning autism	7
GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients	7
Impact of bladder cancer family history on the prognosis of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)	7
Pharmacotherapy for gastric and intestinal cramping pain: ‎ current and emerging therapies	7
The pharmacological management of treatment-resistant depression: what does the future hold?	7
Advances in the pharmacological management of acute myeloid leukemia in adults	7
Guidance for the pharmacological management of COVID-19 in the emergency setting	7
Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients	7
State-of-the-art and emerging antivirals for chronic hepatitis B infection	7
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments	7
Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs	7
Polypharmacology of carbonic anhydrase inhibitors and activators	7
The pharmacological management of alcohol-related cirrhosis: what’s new?	7
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond	7
Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?	7
Advances in pharmacotherapy for bronchiectasis in adults	7
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?	7
Paxlovid as a potential treatment for long COVID	6
Novel pharmacotherapy for drug-induced immune hemolytic anemia	6
Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what’s new on the horizon?	6
Liposomal drug formulations for treatment of hematological malignancies	6
An overview of the current drug treatment strategies for moderate to severe, chronic malignant tumor-related pain	6
Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension	6
Expert guidance for treating anemia in chronic kidney disease: what is the appropriate drug treatment strategy?	6
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4	6
An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer	6
Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC)	6
Valbenazine for the treatment of chorea associated with Huntington’s disease	6
Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection	6
Current factor IX replacement options for hemophilia B and the challenges ahead	6
A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry’s Disease	6
An update on inclisiran for the treatment of elevated LDL cholesterol	6
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?	6
Cardio-reno-vascular protection in type 2 diabetes mellitus: new insights into pharmacotherapeutic management	6
Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine	6
Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome	6
Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia	6
What are the pharmacological considerations for male congenital hypogonadotropic hypogonadism?	6
Perspectives on the currently available pharmacotherapy for wet macular degeneration	6
Investigating cefepime/taniborbactam for the treatment of complicated urinary tract infections	6
BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes	6
Montelukast as a potential treatment for COVID-19	6
The first five years of SARS-CoV-2: inpatient treatment updates and future directions	6
How far are we from an approved drug for nonalcoholic steatohepatitis?	6
Ivosidenib in acute myeloid leukemia	6
The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis	6
Streptozotocin in pancreatic neuroendocrine tumors: a focus on efficacy and safety	6
Clinical challenges and considerations in pharmacotherapy of osteoporosis due to menopause	6
Does standard pharmacotherapy still have a major role in the treatment of aggressive B-cell malignancies?	6
Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder	6
An update on the pharmacotherapy of osteoporosis	6
What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease?	6
Efficacy and safety of pitolisant in children above 6 years with narcolepsy	6
An evaluation of the available pharmacotherapy for the treatment of hirsutism	6
Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature	6
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials	6